Poorly controlled hyperglycemia in type 2 diabetes mellitus (T2DM) portends a high risk for serious, avoidable cardiovascular (CV) and renal complications. This case-based activity for NPs and PAs illustrates the role of sodium-glucose cotransporter-2 (SGLT2) inhibitors, the most recent addition to the practicing clinician’s T2DM armamentarium, highlighting not only their utility in glycemic control, but their demonstrated significant CV advantage in patients with T2DM and established macrovascular complications.
Interactive case study
After completing this activity, participants should be better able to:
- Evaluate the appropriate use of SGLT2 inhibitors based on clinical trial evidence of glycemic and nonglycemic end points and safety
- Integrate SGLT2 inhibitors into T2DM management through personalized treatment to optimize blood glucose control
- Implement national guideline recommendations and evidence-based strategies to provide individualized and patient-centered management of T2DM
Nurse practitioners and physician assistants
There are no prerequisites to participate in this activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.0, which are eligible for 1.0 pharmacology credits.
Course director: Jason Worcester, MD, Boston University School of Medicine
CNE course advisor: Claire Murphy, MSN, NP-C, Boston University School of Medicine
This program has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of March 31, 2018. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program was cosupported by educational grants from Amgen; Astellas; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; ER/LA Opioid Analgesic REMS Program Companies; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; and Sanofi US.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the American Academy of Physician Assistants, Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Inzucchi: clinical trial publications/steering/executive committee: AstraZeneca, Boehringer Ingelheim, Eisai (TIMI), Novo Nordisk, Sanofi/Lexicon; consultant: vTv Therapeutics; data monitoring committee: Intarcia.
The Planning Committee for this activity included Patti-Ann Collins, DNP, MSN, MBA, RN (Lead Nurse Planner), of Healthcare Advocacy Services; Mark Christiansen, PhD, PA-C, of the University of the Pacific; Claire Murphy, MSN, NP-C, Jason Worcester, MD, Jody Walker, MS, and Julie L. White, MS, of Boston University School of Medicine; and Ruth Cohen and Warren Beckman of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Complete the interactive case study
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: March 31, 2018
Expiration date: March 30, 2019
Internet Explorer 8.0+ for Windows 2000, 2003, XP, Vista, or Windows 7, 8, or 10
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5+
© 2018 Practicing Clinicians Exchange. All Rights Reserved. CPCE91317-7C